Pune Magazine

DelveInsight Business Research LLP

DelveInsight’s “Wet Age-Related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Wet Age-Related Macular Degeneration, historical and forecasted epidemiology as well as the Wet Age-Related Macular Degeneration market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Wet Age-Related Macular Degeneration Overview

Wet Age-Related Macular Degeneration (AMD) is a common macular disease that develops when abnormal blood vessels grow into the retina and macula. These leak blood or fluid, which leads to scarring of the macula and rapid loss of central vision. This leakage causes permanent damage to light-sensitive retinal cells (photoreceptors) in the macula and creates a central blind spot (scotoma) in the affected person’s visual field. Aging is a primary risk factor for wet AMD. Each decade of life after age 40 significantly increases one’s risk for the disease. The major risk factors for Wet AMD include Heredity, smoking, Obesity, Inactivity, and High blood pressure.

Wet Age-Related Macular Degeneration Epidemiology Insights

• The prevalence of AMD varies greatly by ethnicity, with non-Hispanic White Europeans having the greatest disease burden. In this review, we refer to race and ethnicity as given by the authors of the original studies. We do not attempt to standardize the designations, as each study has its own method for classifying participants. 

• A recent study by Wong et al. calculated pooled prevalence of ethnically diverse population-based studies of AMD (age range of 45–85 years) and confirmed that prevalence was greatest among those individuals of European descent at 12.3–30% with increasing age. Disease burden, although slightly less, is still great amongst Hispanics (10.4%), Africans (7.5%), and Asians (7.4%) . Still, others have estimated a lower disease burden within the U.S., with non-Hispanic White Europeans having the highest at almost 7.3% and African-Americans at 2.4% . Regardless, it is clear that the prevalence of AMD varies by ethnicity and racial group, and therefore the role of genetic variants, environmental exposures, and their interplay in AMD susceptibility will likely vary by ethnicity as well.

Click here to learn more about the Wet Age-Related Macular Degeneration Market Landscape

The Report Covers the Wet Age-Related Macular Degeneration Epidemiology Segmented by:

• Wet Age-Related Macular Degeneration total prevalent cases 

• Wet Age-Related Macular Degeneration total diagnosed cases 

• Wet Age-Related Macular Degeneration total treatment cases 

• Wet Age-Related Macular Degeneration total incident cases 

Wet Age-Related Macular Degeneration Market Outlook 

The Wet Age-Related Macular Degeneration market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Wet Age-Related Macular Degeneration market trends by analyzing the impact of current Wet Age-Related Macular Degeneration therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the Wet Age-Related Macular Degeneration market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Wet Age-Related Macular Degeneration market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Wet Age-Related Macular Degeneration market in 7MM is expected to change significantly from 2019-2032.

Key Companies Working in the Wet Age-Related Macular Degeneration Market

• Regeneron Pharmaceuticals

• Novartis

• Pfizer

• Roche

• Chengdu Kanghong Biotech

• Kodiak Sciences Inc.

• Opthea Limited

• Alkahest Inc

And many others 

 Wet Age-Related Macular Degeneration Therapies:

• Ranibizumab

•  Lucentis

• Aflibercept 

• Sirolimus

• ALS-L1023

• OPT-302

• Lucentis

And many others 

Learn more about the Key Companies and Emerging Therapies in the Wet Age-Related Macular Degeneration  Market

Table of Contents 

1. Key Insights 

2. Wet Age-Related Macular Degeneration  Introduction 

3. Executive Summary of Wet Age-Related Macular Degeneration   

4. Disease Background and Overview

5. Epidemiology and patient population

6. Wet Age-Related Macular Degeneration  Emerging Therapies

7. Wet Age-Related Macular Degeneration  Market Outlook

8. Market Access and Reimbursement of Therapies

9. Market Drivers 

10. Market Barriers 

11. Appendix

12. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

Learn about the detailed offerings of the report @ Wet Age-Related Macular Degeneration  Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services